More than 100 West Virginia cities and counties have reached a $400 million settlement with drug distributors McKesson, AmerisourceBergen and Cardinal Health, resolving allegations that the companies recklessly oversupplied West…
Gilead Sciences’ Biktarvy, a three-component antiviral, suppressed HIV infections in 99 percent of patients who took it as part of two phase 3 studies. There were no treatment failures, the…
Sanofi has failed to convince a federal appeals court that Viatris monopolized the market for injected epinephrine through anticompetitive pricing for its EpiPen. Source: Drug Industry Daily
Swiss biotech ObsEva has announced a corporate restructuring and layoffs following a notice from the FDA that the company’s new drug application (NDA) for its lead candidate linzagolix for uterine…
After less than stellar interim results from a phase 3 trial focused on head and neck cancer, AstraZeneca is calling it quits in the indication for the checkpoint inhibitor it…